Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn will present at the H.C. Wainwright Bioconnect Conference on January 10, 2022, at 7:00 AM ET. The presentation will be available for on-demand viewing for 30 days via the provided webcast link and the Company’s website. Osmotica focuses on developing pharmaceutical products for underserved markets, with additional operations in Hungary.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was +3.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows:
| Date: | Monday, January 10, 2022 |
| On Demand Time: | 7:00AM ET |
| Webcast: | https://journey.ct.events/view/b39a70c0-7058-4a1f-ba97-e18b13918fc7 |
The presentation will be webcast on-demand and available for 30 days thereafter using the link provided above and via the Company’s website at www.osmotica.com under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting UPNEEQ®.
Osmotica has operations in the United States and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.